EE200200277A - Crystal of 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline as CETP inhibitor - Google Patents
Crystal of 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline as CETP inhibitorInfo
- Publication number
- EE200200277A EE200200277A EEP200200277A EEP200200277A EE200200277A EE 200200277 A EE200200277 A EE 200200277A EE P200200277 A EEP200200277 A EE P200200277A EE P200200277 A EEP200200277 A EE P200200277A EE 200200277 A EE200200277 A EE 200200277A
- Authority
- EE
- Estonia
- Prior art keywords
- carboxyamino
- tetrahydroquinoline
- ethyl
- crystal
- cetp inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 | |
PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200277A true EE200200277A (en) | 2003-10-15 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200277A EE200200277A (en) | 1999-11-30 | 2000-11-14 | Crystal of 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline as CETP inhibitor |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (en) |
JP (1) | JP2003515592A (en) |
KR (1) | KR20020058057A (en) |
CN (1) | CN1402711A (en) |
AP (1) | AP2002002531A0 (en) |
AU (1) | AU1048801A (en) |
BG (1) | BG106854A (en) |
BR (1) | BR0015836A (en) |
CA (1) | CA2392979A1 (en) |
CO (1) | CO5271716A1 (en) |
EA (1) | EA200200510A1 (en) |
EC (1) | ECSP003792A (en) |
EE (1) | EE200200277A (en) |
GT (1) | GT200000199A (en) |
HU (1) | HUP0203521A2 (en) |
IL (1) | IL149097A0 (en) |
IS (1) | IS6338A (en) |
MA (1) | MA26845A1 (en) |
MX (1) | MXPA02005354A (en) |
NO (1) | NO20022558L (en) |
OA (1) | OA12099A (en) |
PA (1) | PA8506301A1 (en) |
PE (1) | PE20010904A1 (en) |
PL (1) | PL355892A1 (en) |
TN (1) | TNSN00231A1 (en) |
TR (1) | TR200201446T2 (en) |
UY (1) | UY26454A1 (en) |
WO (1) | WO2001040190A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
EP1453544A2 (en) * | 2001-06-21 | 2004-09-08 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
GT200200170A (en) | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
MXPA04007438A (en) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials. |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
CA2472028C (en) * | 2002-02-01 | 2010-03-30 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
MXPA05003456A (en) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases. |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
EP1961419B1 (en) | 2002-12-20 | 2010-03-24 | Pfizer Products Inc. | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
MXPA05010456A (en) * | 2003-03-28 | 2006-03-21 | Pfizer Prod Inc | 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity. |
MXPA06001417A (en) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials. |
BRPI0414186A (en) | 2003-10-08 | 2006-10-31 | Lilly Co Eli | compounds, methods of antagonizing cetp activity, treating or preventing a disease, lowering plasma ldl cholesterol in a mammal, treating and / or preventing pathological sequelae, pharmaceutical formulation, and use of a compound |
JP4922924B2 (en) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | CETP inhibitor |
CA2570688A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
WO2006091674A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AR065670A1 (en) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
RU2703192C2 (en) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Genetic markers for predicting response to therapy by raising hdl level or imitating hdl agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Application Discontinuation
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Also Published As
Publication number | Publication date |
---|---|
UY26454A1 (en) | 2001-07-31 |
KR20020058057A (en) | 2002-07-12 |
CO5271716A1 (en) | 2003-04-30 |
BR0015836A (en) | 2002-08-06 |
GT200000199A (en) | 2002-05-23 |
ECSP003792A (en) | 2002-04-23 |
BG106854A (en) | 2002-12-29 |
AP2002002531A0 (en) | 2002-06-30 |
IS6338A (en) | 2002-04-12 |
PA8506301A1 (en) | 2002-08-26 |
NO20022558D0 (en) | 2002-05-29 |
NO20022558L (en) | 2002-05-29 |
PL355892A1 (en) | 2004-05-31 |
CN1402711A (en) | 2003-03-12 |
MXPA02005354A (en) | 2002-12-11 |
OA12099A (en) | 2006-05-04 |
HUP0203521A2 (en) | 2003-02-28 |
WO2001040190A1 (en) | 2001-06-07 |
PE20010904A1 (en) | 2001-09-10 |
TNSN00231A1 (en) | 2002-05-30 |
AU1048801A (en) | 2001-06-12 |
CA2392979A1 (en) | 2001-06-07 |
JP2003515592A (en) | 2003-05-07 |
EP1246804A1 (en) | 2002-10-09 |
IL149097A0 (en) | 2002-11-10 |
TR200201446T2 (en) | 2002-11-21 |
EA200200510A1 (en) | 2002-10-31 |
MA26845A1 (en) | 2004-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200277A (en) | Crystal of 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline as CETP inhibitor | |
EE200100166A (en) | 4-Carboxyamino-2-substituted 1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
EE200100167A (en) | 4-amino-substituted 2-substituted 1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
EE200200140A (en) | Pteridinones as kinase inhibitors | |
NO20013003D0 (en) | Quinoline derivatives | |
ATE228505T1 (en) | QUINOLINE DERIVATIVES | |
IS5775A (en) | Quinoline derivatives | |
DK1114033T3 (en) | 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
NO20016319L (en) | VLA-4 inhibitor compounds | |
NO20006039L (en) | Process for Preparation of 4-Carboxyamino-2-Substituted-1,2,3,4-Tetrahydroquinoline | |
CY2009001I1 (en) | NEW CRYSTAL FORM OF THE PYRROLIDYLTHIOCARBAPENEM DERIVATIVE | |
ATE229005T1 (en) | QUINOLINE DERIVATIVES | |
EE200100039A (en) | Phthalazine derivatives as phosphodiesterase-4 inhibitors | |
NO20023013L (en) | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | |
EE200300266A (en) | Substituted 8-arylquinolines as phosphodiesterase-4 inhibitors | |
DE60107074D1 (en) | CRYSTALLINE FORM II OF CABERGOLIN | |
ATE339438T1 (en) | SUBSTANTIAL CRYSTALLINE FORM OF MELAGATRAN | |
NO20022564D0 (en) | New androgens | |
ATE243197T1 (en) | CRYSTAL FORMS OF OSANETANT | |
IL143779A0 (en) | Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation | |
NO20013407D0 (en) | Process for the preparation of quinoline carbaldehyde | |
DE50003014D1 (en) | N-SUBSTITUTED PERHYDRODIAZINE | |
DK1224179T3 (en) | Sodium-hydrogen yields type 1 inhibitor crystals | |
DE60038936D1 (en) | single crystal | |
DE60014760D1 (en) | Use of primaquine derivatives for the treatment of malaria |